COMPLETE LISTING OF CLAIMS

1.   (Original) A method of treating patients who have diseases characterized bone loss comprising the step of administering to said patient an amount of TRANCE/RANK inhibitors effective to inhibit osteoclastogenesis and/or osteoclast function.

2.   (Original) The method of claim 1 wherein said TRANCE/RANK inhibitor is a compound having the Formula I wherein:

> R_1, and R_2 are, independently, selected from the group consisting of -H, - OCH_3, -CHZCH_3, -t-butyl, 3-carboxy-4-chlorophenylamino, -N-$(CH_2CH_2OH)_2$, and -O(O)C-Ph;

> R_3 is selected from the group consisting of -H, ethyl, -OCH3, -Cl, Br, F, 3carboxy-4-chlorophenylamino, -N-$(CH_2CH_2OH)_2$, -t-butyl, and -OC(O)-Ph, and is not limited to attachment at any certain position on the phenyl ring to which it is attached; and

> R_4 is selected from the group consisting of -Br,-Cl, and -F.

3.   (Original) The method of claim 2 wherein R_3 is attached at either the 1 or 4 position of the 15 phenyl ring.

4.   (Original) The method of claim 1 wherein

> R_1, R_2, and R_3 are -OCH_3, R_3 is attached at the 4 position, R_4 is -Cl; R_1, and R_2 are methyl, $R3$ is ethyl, attached at the 4 position, R_4 is -Cl R_1, and R_2 are -OCH_3, R_3 is -Cl, attached at the 2 position, R_4 is -Cl; R_1, and R_2 are -OCH_3 and R_3 is H, R_4

is -Cl; R_1, is H, R_2 and R_3 are 3-carboxy-4-chlorophenylamino, and R_3 is attached at the 4 position, R_4 Is -Cl; R, and R_2 are -$N(CH_2CH_2OH)_2$, R_3 is Cl, attached at the 4 position, R_4 is -Cl; R_1, R_2, and R_3 are t-butyl, R_3 is attached at the 4 position, R_4 is -Cl; R_1, is -OCH_3, R_2 and R_3 are H, R_4 is Cl; or R,, R_2, and R_3 are benzoate, R_3 is attached at the 4 position, R_4 is -Br.

5. (Original) The method of claim 1 wherein said TRANCE/RANK inhibitor is selected from the group consisting I-A, I-B, I-C, I-D, I-E, I-F, I-G, I-H and I-I.

6. (Original) The method of claim 1 wherein said TRANCE/RANK inhibitor is a compound having the Formula II wherein:

    R_1 is selected from the group consisting of -diphenylchloro methyl, -di(4chlorophenyl)chloro methyl, and 4-(diphenylchloromethyl)phenyl; and R_2, R_3, R_4 are independently selected from the group consisting of -Br, -Cl, and -F.

7. (Original) The method of claim 6 wherein R_2, R_3, R_4 are each -Cl.

8. (Original) The method of claim 1 wherein the TRANCEIRANK inhibitor is selected from the group consisting compounds II-A, II-B, II-C and II-D.

9. (Original) The method of claim 1 wherein said inhibitor is a compound having Formula III wherein:

    R_1 = $(NO_2)_2$, $O(CO)CH_3$, OH, $O(CO)CH_3$, $O(CO)(CH_2)_2COOH$, $O(CO)CH_2Br$, $O(CO)CH_2CI$, $O(CO)CH_2N(CH_3)_3$, or OC_5H_9O; R_2= $CH_2O(NO_2)$, CHO,

$CH_2O(NO_2)$, CN, CH_3, COOH, CHNOH,

$CH_2O(CO)(CH_2)_2COOH$, $CHN(NH)CONH_2$, $CHN(NH)C_6H_5$,

$CHN(CH_2)C_6H_5$, $CH_2N(CH_2)_2OH$, $CH_2NC_6H_5$, or

$CH_2N(NH)CSNH_2$;

R_3= OH, or H;

R_4= CH_3;

R_5= OH;

R_6 = $C_4H_3O_2$, $N(NHCO)C_6H_4Cl$, $N(NHCO)C_6H_4F$, COOH, O,

$COCH_3$, $CH(CH_3)(CH_2)_2COOH$, $CH(CH_3)(CH_2)_2COOCH_3$,

$O(CO)C_6H_5$, or OH;

R_7,= $O(CO)CH_2N(CH_3)_3$, or $O(CO)CH_3$;

R_8= OH;

R_9= O, or OH; and R_{io}=O

R_{10} = O.

10.   (Original) The method of claim 1 wherein the inhibitor is selected from
the group consisting compounds III-1 to III-31.

11.   (Original) The method of claim 1 wherein said inhibitor is a compound
having Formula IV wherein:

R_1, = $O(CO)(CH_2)_2COOH$, or $O(CO)CH_2Br$; and

R_2= $O(CO)(CH_2)_2COOH$, or $O(CO)CH_2Br$.

12.   (Original) The method of claim 1 wherein the inhibitor is selected from
the group consisting compounds IV-1 and IV-2.

13.   (Original) The method of claim 1 wherein said inhibitor is a compound having Formula V wherein:

$R_1 = O$, OH, or $O(CO)CH_3$;

$R_2 = O(CO)CH_3$, OH, $CO(CH_3)$, or $CO(CH_2)O(CO)CH_3$;

$R_3 = CH_3$, or OH; and

$R_4 = O(CO)CH_2C_6H_4I$, or CH_3.

14.   (Original) The method of claim 1 wherein the inhibitor is selected from the group consisting compounds V-1 and V-5

15.   (Original) The method of claim 1 wherein said inhibitor is a compound having Formula VI wherein:

$R_1 = O(CO)CH_3$, OH, or $O(CO)(CH_2)_2COOH$;

$R_2 = CH_3$;

$R_3 = O$, or OH;

$R_4 = CH_3$;

$R_5 = C_9H_{13}COCH_3$, $C_9H_{13}(CH_2CH_3)(CH_2OH)$,

$C_9H_{13}(CH_2CH_3)(CH_2000CH_3)$, $C_9H_{13}(CH_2CH_3)(CH_2$
$OCO(CH_2)_2COOH)$, $C_9H_{13}(CH_2CH_3)(COOH\}$, or
$C_8H_7O(CH_3)(C_4H_90CH_3)$;

$R_6 = CH_3$;

$R_7 = O$, or H;

$R_8 = CH_3$;

$R_9 = (CH_3)_2$; and

$R_{10} = Br$.

16.   (Original) The method of claim 1 wherein the inhibitor is selected from the group consisting compounds VI-1 and VI-11.

17.   (Original) The method of claim 1 wherein the inhibitor is selected from the group consisting compounds VII, VIII IX, X, XI and XII.

Claims 18-43   (Cancelled)

*   *   *   *   *